Pneumonia Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Pneumonia Therapeutics Market is segmented By Type (Community-acquired Pneumonia, Hospital-acquired Pneumonia, Healthcare-associated Pneumonia, Ventilator-associated Pneumonia, Aspiration Pneumonia), By Treatment (Prevention Vaccines, Antibacterial Drugs, Antifungal Drugs, Antiviral Drugs), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Pneumonia Therapeutics Market Overview

Global Pneumonia Therapeutics Market is expected to reach at a CAGR of 7.5% during the forecast period 2024-2031.

Pneumonia is characterized by inflammation and fluid accumulation in the lungs which is caused by a bacterial, viral, or fungal infection. Bacterial pneumonia tends to be more common and more severe than viral pneumonia. Pneumonia is a common illness, with millions of people diagnosed each year in the United States.

The global pneumonia therapeutics market has witnessed significant growth in recent years due to the usage of the Ceftolozane/tazobactam drug that is licensed for the treatment of pneumonia at a dosage of 3 g every 8 hours. Pneumonia symptoms can range from mild to serious which include a cough with or without mucus, fever, chills, and trouble breathing.

Furthermore, significant growth drivers such as increasing product approvals, and research and developments give rise to future market growth. Significant key players like Pfizer Inc., LGM Pharma LLC, Teva Pharmaceuticals Ltd., Sanofi S.A, Baxter International Inc., and others are actively operating in the market.

Pneumonia Therapeutics Market Scope

For more details on this report Request for Sample

Pneumonia Therapeutics Market Dynamics

Rising product approvals for pneumonia treatment

Pneumonia infection makes it difficult to breathe and can cause a fever and cough with yellow, green, or bloody mucus. The product approvals by major companies help to drive market growth and these product approvals help in getting new treatments and improve care for millions of people with pneumonia infections.

For instance, in May 2023, Innoviva Specialty Therapeutics, Inc. declared that the U.S. Food and Drug Administration (FDA) approved XACDURO co-packaged for intravenous use in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Additionally, in January 2023, Alkem Laboratories launched an antibiotic drug Zidavi, a novel combination of ceftazidime and avibactam which is indicated for various ailments like complicated urinary tract infections and as an effective alternative to meropenem and colistin in hospital-acquired pneumonia (HAP). Thus, owing to the above factors the market is expected to boost over the forecast period.

Increasing technological advancements for pneumonia treatment

The global pneumonia therapeutics market has witnessed significant growth due to various recent technological advancements. Pneumonia is usually diagnosed on the basis of medical history and clinical and imaging findings. Also, advanced technological advancements in treating severe pneumonia cases help to accelerate market growth.

For instance, in December 2022, a research team at Swansea University developed an AI-ENABLED SYSTEM called ‘digital twin’ to help prioritize treatment for pneumonia patients who require urgent intensive care and ventilator support. This new innovative system is potentially seen more quickly and receives the most effective treatment based on data from previous pneumonia sufferers. It can also provide real-time feedback on how a patient’s health is likely to vary based on their current known condition using periodic input data from the patient’s vitals such as heart rate, and respiration rate.

Side effects associated with antibiotic drugs are expected to hamper global market growth

There are multiple types of antibiotics that commonly used to treat pneumonia infections and and can have some uncomfortable side effects. These can include gastrointestinal discomfort such as nausea, vomiting, diarrhea, upset stomach, loss of appetite, clay-colored stools, and stomach pain. It can also cause skin issues like hives, yeast infections including oral thrush, and allergic reactions. Thus, the above factors are expected to hamper the market growth.

Pneumonia Therapeutics Market Segment Analysis

The global pneumonia therapeutics market is segmented based on type, treatment, route of administration, distribution channel, and region.

Antibacterial drugs from the treatment segment accounted for approximately xx% of the global pneumonia therapeutics market share

Antibacterial Drugs are expected to hold the largest market share over the period forecast owing to increasing clinical trials of bacterial pneumonia treatment drugs. A total of 324 clinical trials were performed for the treatment of community-acquired pneumonia. For instance, according to clinicalTrials.gov, on July 3, 2023, Paratek Pharmaceuticals Inc. conducted a clinical trial on Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia. The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia. The intervention includes antibacterial drugs Omadacycline and Moxifloxacin IV for injection, and oral tablets.

Additionally, on March 8, 2023, Evopoint Biosciences Inc., conducted a clinical trial on Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants with Bacterial Pneumonia. The study aims to compare treatment with Imipenem/Cilastatin-XNW4107 (IMI-XNW4107) with imipenem/cilastatin/relebactam (IMI/REL) in participants with hospital-acquired or ventilator-associated bacterial pneumonia.

Pneumonia Therapeutics Market Geographical Share

North America accounted for approximately 38.4% of the market share in 2022

The global pneumonia therapeutics market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa. North America has maintained a significant proportion of the pneumonia therapeutics market in recent years, and this trend is anticipated to continue throughout the forecast period due to factors such as the rising incidence of pneumonia diseases, product approvals, and research and developments in pneumonia therapeutics.

For instance, according to the Centers for Disease Control and Prevention 2022, pneumococcal pneumonia causes an estimated 150,000 hospitalizations each year in the United States. The number of visits to emergency departments with pneumonia as the primary diagnosis is 1.5 million and 50,000 deaths from pneumonia disease every year.

In June 2023, Eagle Pharmaceuticals, Inc. declared that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) Designation under the Generating Antibiotic Incentives Now (GAIN) Act and Fast Track Designation for CAL02, a first-in-class non-biological bacterial virulence neutralizer, anti-infective agent being developed to treat severe community-acquired bacterial pneumonia (SCABP) as an add-on therapy to standard of care.

Additionally, in June 2021, The FDA has approved omadacycline, an oral-only dosing regimen, for the treatment of community-acquired bacterial pneumonia. Omadacycline is a novel antibiotic with once-daily oral and IV formulations for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the global pneumonia therapeutics treatment market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in pneumonia therapeutics research and product launches. Clinical trials are vital for developing new treatments and improving outcomes in the pneumonia therapeutics market.

However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies. Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the pneumonia therapeutics market is expected to be moderately affected over the forecast period.

Pneumonia Therapeutics Market Companies

The major global players in the market include Pfizer Inc., Dr. Reddy's Laboratories, LGM Pharma LLC, Teva Pharmaceuticals Ltd., AdvaCare Pharma, Baxter International Inc., Innoviva Specialty Therapeutics Inc., F. Hoffmann-La Roche Ltd, Sanofi S.A, Lupin Limited among others.

Key Developments

• In January 2023, Aeolian Biotech Corp. launched an improved pneumococcal conjugate vaccine, ‘iPCV22’, to address the threat of circulating and emerging pneumococcal serotypes. Aeolian’s iPCV22 vaccine potentially covers 95 percent of invasive pneumococcal disease in adults.
• In May 2023, Gates Foundation funded $200M to develop affordable childhood vaccines and to support delivery of vaccines to prevent pneumonia, meningitis, and neonatal sepsis.
• In June 2023, Aridis Pharmaceuticals, Inc. reported that its AR-301 clinical program is being considered for availing the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs. AR-301, ARDS’ proprietary monoclonal antibody candidate was developed as an adjunctive therapy to be implemented along with standard-of-care antibiotics for the treatment of pneumonia caused by Gram-positive bacteria, Staphylococcus aureus.

Why Purchase the Report?

• To visualize the global pneumonia therapeutics market segmentation based on type, treatment, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global pneumonia therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global pneumonia therapeutics market report would provide approximately 69 tables, 71 figures, and 195 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies